Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCAI-001 in Dry Eye Disease
NCT05733624Phase 2Completed
- Sponsor
- SCAI Therapeutics
- Start
- Jan 2023
- Primary completion
- Aug 2023
- Modality
- Classical Binding Small Molecules, Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SCAI-001 in dry eye disease (DED), sponsored by SCAI Therapeutics. Started Jan 2023; status: completed.
02
Drugs
SCAI-001
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT05733624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05733624.